Header

UZH-Logo

Maintenance Infos

Melanoma of unknown primary: new perspectives for an old story


Boussios, Stergios; Rassy, Elie; Samartzis, Eleftherios; Moschetta, Michele; Sheriff, Matin; Pérez-Fidalgo, José Alejandro; Pavlidis, Nicholas (2021). Melanoma of unknown primary: new perspectives for an old story. Critical reviews in oncology/hematology, 158:103208.

Abstract

Melanoma of unknown primary site (MUP) comprises 3-4 % of all melanomas. It mostly presents in lymph nodes (LNs), followed by subcutaneous sites, and visceral organs; nevertheless, there is a trend of increase in the relative incidence of visceral counterpart in recent years. Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression at the primary site. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors. The survival rate of patients with MUP has been compared to those with stage-matched MKP. Multiple studies conducted before the era of novel therapy with immune checkpoint or BRAF/MEK inhibitors found improved survival in favor of MUP, whereas others reported equivalent or poorer outcomes. Here, we discuss the genetic and molecular features, epidemiology, diagnosis, prognostic factors, survival, and treatment of MUP in comparison with MKP, in the pre- and post-novel therapy era.

Abstract

Melanoma of unknown primary site (MUP) comprises 3-4 % of all melanomas. It mostly presents in lymph nodes (LNs), followed by subcutaneous sites, and visceral organs; nevertheless, there is a trend of increase in the relative incidence of visceral counterpart in recent years. Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression at the primary site. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors. The survival rate of patients with MUP has been compared to those with stage-matched MKP. Multiple studies conducted before the era of novel therapy with immune checkpoint or BRAF/MEK inhibitors found improved survival in favor of MUP, whereas others reported equivalent or poorer outcomes. Here, we discuss the genetic and molecular features, epidemiology, diagnosis, prognostic factors, survival, and treatment of MUP in comparison with MKP, in the pre- and post-novel therapy era.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

0 downloads since deposited on 04 Feb 2021
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Oncology, Geriatrics and Gerontology, Hematology, General Medicine
Language:English
Date:1 February 2021
Deposited On:04 Feb 2021 15:39
Last Modified:04 Feb 2021 15:41
Publisher:Elsevier
ISSN:1040-8428
OA Status:Closed
Publisher DOI:https://doi.org/10.1016/j.critrevonc.2020.103208

Download

Closed Access: Download allowed only for UZH members